CClinicalTrials.gg
CompletedNCT03792880TELESASUpdated Apr 26, 2022

Global Self-management Telematic Support for Patients With Obstructive Sleep Apnea.

An interventional study of Telematic control and self-management program and Habitual follow-up in Healthcare System in Obstructive Sleep Apnea, Telemedicine and Compliance, Patient, sponsored by Virgen del Puerto Hospital. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-26.

Sponsored by Virgen del Puerto Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial compares the usual follow-up to a program of telematic control and self-management in a group of patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS), few symptoms and treated with continuous positive airway pressure (CPAP). The objective of the intervention is to achieve a CPAP compliance of ≥4 hours per day in at least 90% of the subjects.

Read the detailed description

Low CPAP compliance in OSAHS could mean that its possible cardiovascular benefits are not achieved. Telemedicine can be an effective tool to increase CPAP compliance with low cost.

The researchers propose to carry out a randomized study about patients with severe OSAHS and few symptoms, who are expected to have low CPAP compliance.

The main objective is to evaluate if a telematic control and self-management program can increase the compliance with CPAP treatment compared to conventional follow-up, getting at least 90% of patients to use CPAP ≥ 4 hours per day.

Sixty patients from the Pneumology departments of two hospitals, diagnosed with severe OSAHS and with few symptoms (Epworth Sleepiness Scale ≤10) will be randomized to two follow-up groups, telematic and conventional, for 6 months. Patients in the intervention group (telematic monitoring) will collect variables related to symptoms of sleep apnea and side effects of CPAP treatment, using their own smartphone or a tablet provided during the study if they prefer. Other variables as the hours per day of CPAP use, leaks and residual apnea-hypopnea index (AHI) will be transmitted daily and automatically from latest generation CPAP. All information will be processed and each variable will generate alarms and instructions for each patient, allowing the self-management and an early solution of the possible problems related to the treatment. Alarms may also be generated in the database if the professional intervention is necessary.

In addition, before starting CPAP treatment and after six months of treatment, patients will be monitored during a week with a watch-like device. Variables related to circadian rhythm will be collected and analyzed to know the effect of CPAP treatment in both groups (control and intervention groups).

02

Conditions studied

  • Obstructive Sleep Apnea
  • Telemedicine
  • Compliance, Patient

Keywords

  • CPAP treatment
  • Self-management
03

In context

Apnea

1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.

This study's enrollment of 60 is above the median of 50 across 965 interventional studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

This is the only study on the registry with Virgen del Puerto Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a recent diagnostic of OSAHS with AHI≥ 30 and indication of CPAP.
  • Age≥ 18 years
  • Few symptoms, so that, without hypersomnolence (Epworth sleepiness scale ≤ 10)
  • Absence of clinic suspect or confirmation of other sleep pathology
  • With interest in the use of new technologies

Exclusion criteria

Exclusion Criteria:

  • Nasal obstruction that prevents the use of CPAP
  • Psycho-physical inability to complete questionnaires and carry out the program
  • Patients undergoing uvulopalatopharyngoplasty
  • Cheyne-Stoke syndrome
  • Pregnancy
  • Absence of informed consent
  • Shift work in the last 3 months and transmeridian trips in the last month.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Control arm

    Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment

    Behavioral: Habitual follow-up in Healthcare System

  • Experimental
    Intervention arm

    Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program

    Behavioral: Telematic control and self-management program · Behavioral: Habitual follow-up in Healthcare System

Interventions

  • BehavioralTelematic control and self-management program

    During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed. A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring.

  • BehavioralHabitual follow-up in Healthcare System

    According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.

06

What researchers measure

Primary outcomes

  1. Patients with a good CPAP compliance

    Percentage of patients with a CPAP compliance ≥4 hours per day. The main objective is to assess if a self-management and telematic control program can increase CPAP compliance getting at least 90% of patients using CPAP ≥4 hours per day.

    Time frame: Six months

Secondary outcomes

  1. CPAP compliance

    To compare CPAP compliance between both arms using the average compliance (hours of use per day) as secondary variable.

    Time frame: Six months

  2. Dropout

    To compare the dropout percentage between both arms

    Time frame: Six months

  3. Side effects

    To compare the control of side effects between both arms using the percentage of patients who have any of these effects during the follow-up.

    Time frame: Six months

  4. Efficacy of the treatment according to the change in sleepiness

    To compare the efficacy of the treatment using the change of the Epworth Sleepiness Scale score in both arms and between them. This scale is a self-administered questionnaire and patients must rate their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The possible answers for each situation and their scores are: 0 = would never doze; 1 = slight chance of dozing; 2 = moderate chance of dozing; 3= high chance of dozing. The Epworth Sleepiness Scale score is the sum of these 8 items scores and it can be interpreted as follows: 0-5 = lower normal daytime sleepiness; 6-10 = higher normal daytime sleepiness; 11-12 = mild excessive daytime sleepiness; 13-15 = moderate excessive daytime sleepiness; 16-24 = severe excessive daytime sleepiness.

    Time frame: Six months

  5. Efficacy of the treatment according to the change in the frequency of the snoring.

    To compare the efficacy of the treatment in both arms and between them using the change in the frequency of the snoring according to four levels: never, sometimes, frequently and always or almost always

    Time frame: Six months

  6. Efficacy of the treatment according to the change in the frequency of the witnessed apneas

    To compare the efficacy of the treatment in both arms and between them using the change in the frequency of the witnessed apneas according to four levels: never, sometimes, frequently and always or almost always

    Time frame: Six months

  7. Efficacy of the treatment according to the change in the frequency of the refreshing sleep

    To compare the efficacy of the treatment in both arms and between them using the change in the frequency of the refreshing sleep according to four levels: never, sometimes, frequently and always or almost always

    Time frame: Six months

  8. Presence of air leak and residual AHI

    To compare the intensity of the air leak and residual AHI measured by the CPAP device between both arms.

    Time frame: Six months

  9. Change of quality of life using the change in the EuroQol-5 dimensions-3 levels questionnaire.

    To compare the change of quality of life before and after the follow-up in both arms and between them, using the change in the EuroQol-5 dimensions-3 levels questionnaire. This is a standardised measure of health status that comprises a descriptive system and a visual analogue scale. The first comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1 = no problems; 2 = some or moderate problems; 3 = extreme problems. The health state is defined by combining one level from each dimension (5 digit code). This descriptive system is converted into a single index value facilitating comparisons and the calculation of quality-adjusted life years (QALYs). The visual analogue scale records the respondent's self-rated health on a 20 centimeters vertical, visual analogue scale with endpoints labeled as: 100 = the best health you can imagine and 0. = the worst health you can imagine.

    Time frame: Six months

  10. Effect of the treatment in the quality of sleep using the change in the rhythm of the distal skin temperature.

    To compare the effect of the treatment in the quality of sleep using the change in the rhythm of distal skin temperature by ambulatory circadian monitoring including this variable. The investigators will compare the rhythm of this variable before and after CPAP treatment in both arms and the difference between them. For this propose, all randomized patients will carry a watch-like device for ambulatory circadian monitoring during one week before starting CPAP treatment and during the last week of the six months of follow-up and treatment with CPAP.

    Time frame: Six months

  11. Effect of the treatment in the quality of sleep using the change in the rhythm of activity.

    To compare the effect of the treatment in the quality of sleep using the change in the rhythm of activity by ambulatory circadian monitoring including this variable. The investigators will compare the rhythm of this variable before and after CPAP treatment in both arms and the difference between them. For this propose, all randomized patients will carry a watch-like device for ambulatory circadian monitoring during one week before starting CPAP treatment and during the last week of the six months of follow-up and treatment with CPAP.

    Time frame: Six months

  12. Effect of the treatment in the quality of sleep using the change in the rhythm of exposure to light

    To compare the effect of the treatment in the quality of sleep using the change in the rhythm of exposure to light by ambulatory circadian monitoring including this variable. The investigators will compare the rhythm of this variable before and after CPAP treatment in both arms and the difference between them. For this propose, all randomized patients will carry a watch-like device for ambulatory circadian monitoring during one week before starting CPAP treatment and during the last week of the six months of follow-up and treatment with CPAP.

    Time frame: Six months

  13. Effect of the treatment in the quality of sleep using the change in the result of an integrated analysis of the distal skin temperature, activity and position records.

    To compare the effect of the treatment in the quality of sleep using the change in the result of an integrated analysis of the distal skin temperature, activity and position records obtained by ambulatory circadian monitoring including these variables. The researchers will compare this result before and after CPAP treatment in both arms and the difference between them. For this propose, all randomized patients will carry a watch-like device for ambulatory circadian monitoring during one week before starting CPAP treatment and during the last week of the six months of follow-up and treatment with CPAP.

    Time frame: Six months

  14. Effect of the presence of a couple on the treatment efficacy.

    To compare the efficacy of the treatment according to the presence or not of a couple, comparing the percentage of patients with CPAP compliance ≥4 hours per day between both groups of patients (all patients with and without couple), within each arm (control and intervention arm) and between arms.

    Time frame: Six months

  15. Effect of the age on the treatment efficacy

    To analyze the influence of the patients' age on the percentage of patients with a CPAP compliance ≥4 hours per day in both arms.

    Time frame: Six months

  16. Effect of the gender on the treatment efficacy

    To compare the efficacy of the treatment depending on the gender, comparing the percentage of patients with a CPAP compliance ≥4 hours per day between all men and all women, within each arm and between arms.

    Time frame: Six months

  17. Effect of the CPAP pressure on the treatment efficacy

    To analyze the effect of the CPAP pressure on the percentage of patients with a CPAP compliance ≥4 hours per day in both arms.

    Time frame: Six months

  18. Effect of the type of mask on the treatment efficacy

    To compare the efficacy of the treatment depending on the type of mask used during the CPAP treatment, comparing the percentage of patients with a CPAP compliance ≥4 hours per day in the group of patients who use nasal pillow, full face and nasal mask in both arms and between them.

    Time frame: Six months

  19. Effect of the use of humidifier on the treatment efficacy

    To compare the efficacy of the treatment depending on the use of humidifier during the CPAP treatment, comparing the percentage of patients with a CPAP compliance ≥4 hours per day in the group of patients who use or not humidifier in both arms and between them.

    Time frame: Six months

  20. Effect of the presence of side effects on the treatment efficacy

    To compare the efficacy of the treatment depending on the presence of any side effect during the CPAP treatment, comparing the percentage of patients with a CPAP compliance ≥4 hours per day in the group of patients with and without any side effect in both arms and between them.

    Time frame: Six months

  21. Cost-effectiveness analysis

    The researchers will perform a cost-effectiveness analysis using the average compliance as main variable of effectiveness, and the EuroQol-5 dimensions-3 levels descriptive system to calculate QALYs. EuroQol-5 dimensions-3 levels descriptive system is a standardised measure of health status that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1 = no problems; 2 = some or moderate problems; 3 = extreme problems. The respondent have to indicate his/her health state according to the most appropiate statement in each dimension. The health state is defined by combining one level from each of the 5 dimensions (5 digit code) and then, this descriptive system is converted into a single index value facilitating comparisons and the calculation of quality-adjusted life years (QALYs).

    Time frame: Six months

07

Study locations

2 sites
  • Virgen del Puerto Hospital
    Plasencia, Cáceres 10600, Spain
  • San Pedro de Alcántara
    Cáceres, 10003, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03792880
Lead sponsor
Virgen del Puerto Hospital
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Jun 1, 2019
Primary completion
Dec 28, 2020
Completion
Dec 28, 2021
Last update
Apr 26, 2022

Study contacts

María Ángeles Sánchez Quiroga
principal investigator · Virgen del Puerto Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion